Kedudukan dalam Saham
#17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Perubahan (1 tahun)
-22.01%
Perdagangan Noxopharm Limited (NOX)
Margin Operasi untuk Noxopharm Limited (NOX)
Margin Operasi pada March 2026 TTM: -532.32%
Menurut laporan kewangan dan harga saham terkini Noxopharm Limited, margin operasi semasa (TTM) ialah -532.32%. Pada akhir 2024, margin operasi syarikat ialah -313.92%.
Sejarah Margin Operasi untuk Noxopharm Limited dari 2016 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun |
Margin Operasi |
Ubah |
|
2026 (TTM) |
-532.32%
|
55.59%
|
|
2025 |
-342.14%
|
8.99%
|
|
2024 |
-313.92%
|
13.69%
|
|
2023 |
-276.12%
|
-1.43%
|
|
2022 |
-280.14%
|
7.54%
|
|
2021 |
-260.50%
|
31.83%
|
|
2020 |
-197.61%
|
-52.69%
|
|
2019 |
-417.69%
|
-63.54%
|
|
2018 |
-1,145.69%
|
-55.34%
|
|
2017 |
-2,565.11%
|
0.00%
|
|
2016 |
0.00%
|
0.00%
|
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat |
Margin Operasi |
Perbezaan Margin Operasi |
Negara |
|
|
41.30% |
-100.08%
|
DK
|
|
|
35.45% |
-100.07%
|
US
|
|
|
24.95% |
-100.05%
|
US
|
|
|
25.32% |
-100.05%
|
BE
|
|
|
25.72% |
-100.05%
|
AU
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.
